Physician profile
Ellen Ormond Zummo
NPI 1336741719
$2,431.18
in general payments reported to CMS, 2019-2025
25 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.69 · 2022: $117 · 2023: $1,039 · 2024: $1,043 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,228.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.53 | 2022-2024 | |
| Glaxosmithkline, LLC. | $416.59 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $164.20 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $132.46 | 2023-2024 | Farxiga, Breztri, Flumist Quadrivalent |
| Exact Sciences Corporation | $126.14 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $124.78 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $116.18 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $111.49 | 2022-2024 | Mounjaro, Jardiance |
| Amgen INC. | $108.54 | 2023-2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $106.34 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $61.12 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.63 | 2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $34.01 | 2021 | |
| Lundbeck LLC | $32.73 | 2023 | Rexulti |
| Irhythm Technologies, INC. | $27.32 | 2023 | Zio Xt Patch |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.81 | 2024 | Glassia |
| Urovant Sciences INC | $25.07 | 2022 | |
| Astellas Pharma US INC | $24.89 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.22 | 2023 | |
| Avanir Pharmaceuticals, INC. | $24.13 | 2021 | |
| Eisai INC. | $23.29 | 2024 | |
| Ironwood Pharmaceuticals, INC | $22.34 | 2023 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $18.16 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.68 | 2024 | Rexulti |
| Almatica Pharma LLC | $15.53 | 2023 | Gralise, Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Ormond Zummo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.